AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.
ABCL has been the topic of several other reports. Leerink Partners began coverage on shares of AbCellera Biologics in a research report on Monday. They issued an "outperform" rating and a $5.00 target price on the stock. Truist Financial lowered their target price on AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, KeyCorp lifted their target price on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, AbCellera Biologics has a consensus rating of "Buy" and an average target price of $7.50.
Get Our Latest Report on AbCellera Biologics
AbCellera Biologics Stock Down 3.4%
NASDAQ:ABCL traded down $0.15 during trading hours on Monday, reaching $4.11. 1,718,898 shares of the company's stock were exchanged, compared to its average volume of 3,466,646. The company has a market capitalization of $1.23 billion, a P/E ratio of -7.31 and a beta of 0.62. AbCellera Biologics has a 12 month low of $1.89 and a 12 month high of $4.33. The business's 50-day simple moving average is $2.79 and its two-hundred day simple moving average is $2.76.
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The firm had revenue of $4.24 million during the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative return on equity of 15.98%. As a group, sell-side analysts anticipate that AbCellera Biologics will post -0.59 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Stratos Wealth Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $27,000. DKM Wealth Management Inc. bought a new position in AbCellera Biologics during the fourth quarter valued at approximately $29,000. Janney Montgomery Scott LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $29,000. AssuredPartners Investment Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $34,000. Finally, Balyasny Asset Management L.P. bought a new stake in AbCellera Biologics in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 61.42% of the company's stock.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More

Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.